Genetic alterations in primary glioblastomas in Japan

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 1, 2006, Pages 12-18

  Fukushima, Takao ^a   Favereaux, Alexandre ^a   Huang, Hervé ^a   Shimizu, Tsuneo ^b   Yonekawa, Yasuhiro ^c   Nakazato, Yoichi ^d   Ohagki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b Kanto Neurosurgical Hospital   (Japan)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d GUNMA UNIVERSITY   (Japan)

Author keywords

EGFR amplification; EGFR mutation; LOH 10q; p16INK4a deletion; PTEN mutation; TP53 mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN P16INK4A; PTEN PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CAUCASIAN; CHROMOSOME 10Q; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HIGH RISK PATIENT; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; SCREENING; SINGLE STRAND CONFORMATION POLYMORPHISM; CHI SQUARE DISTRIBUTION; CHROMOSOME 10; COMPARATIVE STUDY; FOLLOW UP; GENETICS; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SWITZERLAND;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CHROMOSOMES, HUMAN, PAIR 10; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; JAPAN; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SURVIVAL RATE; SWITZERLAND; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33644880865     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000196132.66464.96     Document Type: Article

References (29)

1. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-18
2. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-99
3. Ichimura K, Ohgaki H, Kleihues P, Collins VP. Molecular pathogenesis of astrocytic tumours. J Neurooncol 2004;70:137-60
4. Collins VP. Brain tumours: Classification and genes. J Neurol Neurosurg Psychiatry 2004;75(suppl 2):2-11
5. Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004;10:228-33
6. Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma: Prognostic significance and future therapeutic implications. Adv Anat Pathol 2003;10:212-17
7. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89
8. Chen P, Aldape K, Wiencke JK, et al. Ethnicity delineates different genetic pathways in malignant glioma. Cancer Res 2001;61:3949-54
9. Das A, Tan WL, Teo J, Smith DR. Glioblastoma multiforme in an Asian population: Evidence for a distinct genetic pathway. J Neurooncol 2002; 60:117-25
10. Mochizuki S, Iwadate Y, Namba H, et al. Homozygous deletion of the p16/MTS-1/CDKN2 gene in malignant gliomas is infrequent among Japanese patients. Int J Oncol 1999;15:983-89
11. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 1997;94:303-309
12. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997;7:871-75
13. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
14. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-87
15. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-24
16. Tohma Y, Gratas C, Biernat W, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998;57:684-89
17. Arf deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001;11:159-68
18. Nigro JM, Takahashi MA, Ginzinger DG, et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a realtime quantitative polymerase chain reaction assay. Am J Pathol 2001;158:1253-62
19. Parkin DM, Whelan SL, Feraly J, Teppo L, Thomas D. Cancer Incidence in Five Continents. Lyon, France: IARC Press, 2002
20. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon, France: IARC Press, 2000
21. Kuratsu J, Takeshima H, Ushio Y. Trends in the incidence of primary intracranial tumors in Kumamoto, Japan. Int J Clin Oncol 2001;6:183-91
22. McLendon RE, Robinson JS Jr, Chambers DB, Grufferman S, Burger PC. The glioblastoma multiforme in Georgia, 1977-1981. Cancer 1985;56:894-97
23. Stiller CA, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol 1994;23:458-64
24. Fan KJ, Pezeshkpour GH. Ethnic distribution of primary central nervous system tumors in Washington, DC, 1971 to 1985. J Natl Med Assoc 1992;84:858-63
25. Davis FG, McCarthy B, Jukich P. The descriptive epidemiology of brain tumors. Neuroimaging Clin N Am 1999;9:581-94
26. Central Brain Tumor Registry of the United States. Central Brain Tumor Registry of the United States (CBTRUS. Available at: http://www.cbtrus. org. 2002)
27. Chou D, Miyashita T, Mohrenweiser HW, et al. The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 1996;88:136-40
28. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
29. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42